Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Public ClinicalTrials.gov record NCT05687266. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
Study identification
- NCT ID
- NCT05687266
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,350 participants
Conditions and interventions
Conditions
Interventions
- Datopotamab deruxtecan Drug
- Durvalumab Drug
- Carboplatin Drug
- Pembrolizumab Drug
- Cisplatin Drug
- Pemetrexed Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2022 (Actual)
- Primary completion
- Nov 1, 2027 (Estimated)
- Completion
- Nov 1, 2027 (Estimated)
- Last update posted
- Oct 9, 2026
2022 – 2027
United States locations
- U.S. sites
- 52
- U.S. states
- 24
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85054 | — |
| Research Site | Tucson | Arizona | 85704 | — |
| Research Site | Hot Springs | Arkansas | 71913 | — |
| Research Site | Little Rock | Arkansas | 72205 | — |
| Research Site | Springdale | Arkansas | 72762 | — |
| Research Site | Fountain Valley | California | 92708 | — |
| Research Site | Los Angeles | California | 90017 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Boulder | Colorado | 80303 | — |
| Research Site | Fort Myers | Florida | 33901 | — |
| Research Site | Jacksonville | Florida | 32224 | — |
| Research Site | St. Petersburg | Florida | 33705 | — |
| Research Site | West Palm Beach | Florida | 33401 | — |
| Research Site | Hinsdale | Illinois | 60521 | — |
| Research Site | Fort Wayne | Indiana | 46845 | — |
| Research Site | Bettendorf | Iowa | 52722 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Waukee | Iowa | 50263 | — |
| Research Site | Baton Rouge | Louisiana | 70808 | — |
| Research Site | Covington | Louisiana | 70433 | — |
| Research Site | Duluth | Minnesota | 55805 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Hannibal | Missouri | 63401 | — |
| Research Site | Lincoln | Nebraska | 68506 | — |
| Research Site | Lincoln | Nebraska | 68516 | — |
| Research Site | Clifton Park | New York | 12065 | — |
| Research Site | Asheville | North Carolina | 28806 | — |
| Research Site | Canton | Ohio | 44710 | — |
| Research Site | Columbus | Ohio | 43219 | — |
| Research Site | Maumee | Ohio | 43537 | — |
| Research Site | Tulsa | Oklahoma | 74134 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Salem | Oregon | 97301 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | York | Pennsylvania | 17403 | — |
| Research Site | Watertown | South Dakota | 57201 | — |
| Research Site | Memphis | Tennessee | 38120 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | Irving | Texas | 75063 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Henrico | Virginia | 23229 | — |
| Research Site | Norfolk | Virginia | 23502 | — |
| Research Site | Renton | Washington | 98055 | — |
| Research Site | Spokane | Washington | 99202 | — |
| Research Site | Tacoma | Washington | 98405 | — |
| Research Site | Appleton | Wisconsin | 54911 | — |
| Research Site | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 202 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05687266, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05687266 live on ClinicalTrials.gov.